Positron Emission Tomography Study Evaluating Novel Radioligand for Imaging Mutant Huntingtin in Huntington's Disease

The primary objective of this study is to evaluate the suitability of a novel **radioligand** for imaging mutant huntingtin in patients with **Huntington's disease** using Positron Emission Tomography (PET). This is clinically relevant as it may enhance the understanding of disease pathology and progression, potentially aiding in the development of targeted therapies for Huntington's disease.

The clinical trial involves participants diagnosed with **Huntington's disease**. The study population includes both male and female subjects, with an age range categorized as adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been detailed in the available data.

The clinical trial is designed to evaluate the properties of a novel radioligand for imaging **mutant huntingtin** in patients with **Huntington's disease**. This study is a Phase 3 trial, employing a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The trial is expected to commence recruitment on March 1, 2025, and conclude by March 1, 2027, with an overall duration of approximately two years. Participants will be involved in a series of study visits, beginning with an inclusion visit, which serves as a screening to determine eligibility based on predefined criteria. Subsequent follow-up visits will be scheduled to monitor the participants' response to the radioligand and to collect necessary imaging data. The end-of-study visit will mark the completion of the trial for each participant, during which final assessments will be conducted to evaluate the primary and secondary endpoints. The expected length of participant involvement will vary depending on individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse reactions to the radioligand, non-compliance with study procedures, or withdrawal of consent by the participant. The trial aims to provide valuable insights into the imaging capabilities of the radioligand, contributing to the understanding and management of **Huntington's disease**.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is available from the provided data. Consequently, a detailed description of the experimental treatment cannot be provided.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Therefore, a description of these elements is not possible based on the current data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. As such, these aspects cannot be detailed in this description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on March 1, 2025, with an estimated completion date of March 1, 2027. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured methodology to ensure the accurate measurement and analysis of efficacy parameters. The data collection and analysis will adhere to rigorous standards typical of Phase 3 trials, ensuring the reliability and validity of the results. The trial's design and execution will be aligned with regulatory requirements and scientific best practices to evaluate the therapeutic benefits effectively.